The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
|Articles|November 21, 2007
Schering-Plough and Organon merger finalized
Schering-Plough/Organon merger passes antitrust scrutiny and is completed
Advertisement
The Federal Trade Commission has cleared Schering-Plough's acquisition of Organon BioSciences N.V. from Akzo Nobel N.V. with no requirement for any divestitures in human health products. So Schering-Plough announced the merger is now complete. According to Schering-Plough's CEO Fred Hassan, Organon brings to the table two important pharmaceutical franchises, women's health and central nervous system products. In addition, it has several promising phase III compounds in development.
To go to the Drug Topics homepage,
Advertisement
Related to this article
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
Cohort studies found no clear cardiovascular benefit from PPV23 vaccination, leaving its role in cardiovascular prevention unresolved.
A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
A guide built from conversations with pharmacists on social media and independent pharmacy owners.
Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
2
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
3
High-Dose Vaccines Reduce Hospital Stays in Older Adults With Lung Disease
4
PPV23 Vaccination Found to Not Reduce Cardiovascular Risk
5